23-25 October


Keynote speakers

Leading experts in their fields

1250 Participants

In 2017 edition

About Lisbon Addictions 2019

Lisbon Addictions 2019, the third European Conference on Addictive Behaviours and Dependencies, is a multidisciplinary conference that provides a forum for networking across the addictions. Over 1 200 participants from 70 countries attended Lisbon Addictions 2017. See presentations and posters.

#LxAddictions19 will also provide opportunities for early-stage reseachers to enhance their careers. The Programme and Organising Committees have therefore planned to hold dedicated showcase sessions, developed a new concept for poster sessions and will further promote networking activities and mentoring to meet the needs of these participants.

Practical information including directions to the venue (PDF)

What's new?

Guidelines for presenters and chairs available

Practical information available

Outline programme available

1 July–25 October 2019: Late registration (online and on-site – EUR 600)


Guidelines for presenters and chairs (PDF)

The overarching theme for 2019 is 'The future of addictions: new frontiers for policy, practice and science'. The conference will therefore showcase cutting-edge research to help characterise, understand and respond to addiction and addictive behaviours.

The first draft outline of the programme is now available.

Spotlight on co-production

For the #LxAddictions19 we have adopted a new approach to shaping the conference programme. We will work closely with co-producers in order to develop a rich, diverse and innovative programme by taking joint responsibility for organising thematic tracks around selected topics. The co-producers will build coherent packages of topical strands, sessions and guided poster tours.

  • European Federation of Addiction Societies (EUFAS)

    EUFAS will develop a track on ‘Progress in alcohol research and treatment’, focussing on alcohol use and related disorders, covering a broad range from alcohol-use trends, epidemiology of alcohol use disorders to underlying neuroscientific findings and treatment innovations.

  • FuturiZe

    The FuturiZe (FZ) track activities will be hosted in a dedicated area of the conference centre – the Futures Zone – which, as well as hosting sessions on forward-looking trends and topics, such as digitalisation, future drug policy, innovative monitoring and new therapeutic horizons, will be home to hands-on technology demonstrations, participatory brain-writing and interactive workshops with new serious games formats.

  • International Network on Hepatitis in Substance Users (INHSU)

    INHSU will bring together stakeholders in the areas of drug user health and HCV to discuss ‘The future of hepatitis C among people who inject drugs: new frontiers for policy, practice and science’.

  • International Society for the Study of Drug Policy (ISSDP)

    ‘Improving the data, methods and analysis used to inform drug policy’ is the track organised by ISSDP. It will showcase the variety of drug policy approaches being adopted globally to provide evidence for improved policymaking going forward.

  • International Society for the Study of Behavioural Addictions 

    The track co-produced by the International Society for the Study of Behavioural Addictions will introduce non-substance-related disorders (including gambling, problematic video game use, internet addiction, problematic social media use, exercise addiction, compulsive buying behaviour), discuss their phenomenology, etiology, assessment, epidemiology and other relevant characteristics as well as the main problematic issues emerging in connection with these phenomena.

  • Society for the Study of Addiction (SSA)

    This thematic track will focus on opioid-related deaths, mainly in Europe and Australia and will be organised by the SSA. It will include discussion of data from countries where opioid-related deaths have been increasing, as well as emerging trends in terms of age and gender distribution, the contribution of polydrug use, and the proportion of deaths attributable to pharmaceutical opioid drugs..


The EC co-funded project FuturiZe (FZ) will collaborate with the organisers of Lisbon Addictions 2019 by developing networking activities and a series of interactive debates which focus on key future scenarios in the field of drugs and behavioural addictions. The scenarios will be chosen and developed through a participatory process with a wide variety of stakeholders. The FZ debates will be open to all conference participants and introduced in each case by prominent thinkers from different backgrounds and perspectives. The project will also provide bursaries for around 120 multi-sectoral professionals who would otherwise not be able to attend the event.

The FuturiZe future scenarios consultation survey is the first step in a participatory process to develop a set of scenarios and a corresponding series of interactive debates at the Lisbon Addictions 2019 conference.

This survey is a scoping exercise to gather expert opinion and insight into future issues in the area of addictions. Read more >>

Keynote speakers and chairs

Laura d'Arrigo

Diplomatic advisor at the Interministerial Mission for combating drugs and addictive behaviours, Paris, France, Chair of the EMCDDA Management Board

Tom Blickman

Senior Project Officer at the Transnational Institute (TNI), Amsterdam, The Netherlands

Henrietta Bowden-Jones OBE

Director, National Problem Gambling Clinic. President, Medical Women's Federation, UK

Tony Duffin

Chief Executive Officer, Ana Liffey Drug Project, Dublin, Ireland

Niamh Fitzgerald

President, International Network of ATOD Research Associations/University of Stirling, Associate Professor in Alcohol Studies, Institute for Social Marketing, University of Stirling, Stirling, Scotland, UK

Olivier George

Associate Professor & Co Director ARC Animal Core Department of Neuroscience, The Scripps Research Institute, USA

Speaker 5

Eilish Gilvarry

Consultant Psychiatrist in Addictions, Deputy Medical Director, NHS Foundation Trust, Honorary Professor Addiction Psychiatry, Newcastle University, President of SSA, UK

Speaker 6

Johanna Gripenberg

Associated, Research team leader, Center for Psychiatric Research, Karolinska University, Sweden

Antoni Gual

Head of the Addictions Unit, Psychiatry Department, Neurosciences Institute, Hospital Clínic, IDIBAPS, Barcelona, Spain

Speaker 5

Wayne Hall

Centre for Youth Substance Abuse Research, The University of Queensland, Australia, Professor,National Addiction Centre, Kings College London, UK

Marilyn A. Huestis

The Lambert Centre for the Study of Medical Cannabis and Hemps, Institute for Emerging Health Professions, Thomas Jefferson University, Philadelphia, USA

Speaker 6

Axel Klein

Senior Research Fellow at the Global Drug Policy Observatory, Swansea, UK

Speaker 6

Karl E Lund

Senior Researcher, Department of Alcohol, Tobacco & Drugs, Norwegian Institute of Public Health, Oslo, Norway

Angela Morelli

CEO / Co-Founder InfoDesignLab, Oslo, Norway

Robin Murray, FRS

Professor of Psychiatric Research, Institute of Psychiatry, Psychology and Neuroscience, King’s College, London, United Kingdom

Marie Nougier

Head of Research and Communications, International Drug Policy Consortium, London, United Kingdom

Speaker 6

Jennifer Price

Principal Cannabis Compliance Consultant, Abundant Universe, Santa Rosa, California, USA

Florence Ranson

Founder of REDComms, Brussels, Belgium

Mariann Skar

Secretary General, European Alcohol Policy Alliance, Brussels, Belgium

John Strang

Head of Addictions department, King’s College London, United Kingdom

Speaker 6

Paul Wallace

Professor emeritus, University College London, United Kingdom

Speaker 6

Sharon L. Walsh

Director, Center on Drug and Alcohol Research Professor of Behavioral Science, Pharmacology, Pharmaceutical Sciences and Psychiatry University of Kentucky Lexington, KY USA

Side events and networking

#LxAddictions19 will again provide a unique networking opportunity for researchers, practitioners and policy experts across countries and disciplines, addressing new challenges and covering developing fields. In the margins of the conference various major events will take place.

To promote networking, conference rooms will be available for side events. If interested, please contact us at: lisbonaddictions2019@abreu.pt

International symposium on drug checking

The international symposium on drug checking will take place on the 22 October.

Recent changes in Europe’s cocaine and synthetic drugs markets pose a challenge for traditional drug monitoring. Data from drug checking services can provide valuable information on drug market dynamics at user level. However, drug checking as an intervention in recreational settings remains a topic of much debate in the media, among policy makers and researchers worldwide.   

The aims of this symposium are: to explore drug markets dynamics with an international comparison of cocaine and MDMA trends, purity and adulteration in producing and consuming countries through European, Colombian and Australian drug checking test results; and to discuss the challenges and opportunities of drug checking within national drug policies.

Please register now for free to join this symposium and for more information on the agenda. This symposium is organised by the EMCDDA in collaboration with SICAD, COPOLAD and the Trans European Drug Information (TEDI) network.   

9th symposium of the Alcohol Policy Network Europe (APN)

The 9th symposium of the Alcohol Policy Network Europe (APN) will take place on 22 October. The draft agenda includes topics such as: salient alcohol policy developments in selected countries; the role of the industry in alcohol policymaking; and regulating alcohol marketing in electronic media. 

More information will soon be available at www.alcoholpolicynetwork.eu

Health Without Barriers

Health Without Barriers, the European Federation for prison health and human rights in prison, is organising its second European conference on health care in prison in Lisbon on 21 and 22 October. The conference will provide a space for discussion and exchange among health professionals working in prison in European and non-European countries. The participants will come from different disciplines, from practice to research and monitoring, from law enforcement and prison administration to peer involvement, including people with a personal experience of prison. For further information, visit www.healthwithoutbarriers.org

International Cannabis Toolkit Workshop

The International Cannabis Toolkit Workshop will take place on 22 October.

Cannabis products continue to diversify as legal medical and recreational markets expand worldwide. These products vary considerably in THC and CBD concentrations, methods of administration and across different countries. A key problem facing the field is the lack of standardised, validated measures of cannabis use (akin to standard alcohol units). This severely limits our ability to synthesise findings across research studies, to develop guidelines and policies for safer use, and to manage cannabis in treatment settings. This workshop aims to:

  • Identify and disseminate key challenges in measuring cannabis use from an international and multidisciplinary perspective
  • Launch the development of an International Cannabis Toolkit, a standardised, internationally relevant tool for measuring cannabis use in research and clinical settings

The workshop will include a series of expert talks followed by an interactive discussion. Please register now to join this initiative. Further information is available at https://canntoolkit.com/.

This workshop is funded by the Society for the Study of Addiction, the European Monitoring Centre for Drugs and Drug Addiction and the Portuguese General Directorate for Intervention on Addictive Behaviours and Dependencies (SICAD).


Online registration is open. Places for non-presenters will be allocated on a first come, first served basis. All persons intending to attend the conference must register and pay the applicable registration fee, including paper and poster presenters, discussants and chairs.

The conference registration fee is EUR 600. Authors who submitted an abstract for the conference will be informed by e-mail if their contribution has been accepted for inclusion in the conference programme and will have two weeks to register for the conference with the early-bird fee (EUR 400).

Register now >>

Support for participants from European Neighbourhood Policy countries

In order to encourage participation in Lisbon Addictions 2019 for professionals, academics and experts working in European Neighbourhood Policy (ENP) countries, a small number of bursaries will be provided under the ‘EU4Monitoring Drugs’ (EU4MD) project, funded by the European Commission.

The eligible countries are: Algeria, Egypt, Israel, Jordan, Lebanon, Libya, Morocco, Palestine*, Tunisia, Armenia, Azerbaijan, Belarus, Georgia, Moldova and Ukraine.

The bursaries will cover the flight, accommodation and Lisbon Addictions 2019 conference fees. The conference is only in English.

Click here for the bursary application form. The deadline for applications is 27 May 2019. Successful candidates will be notified by 15 June 2019.


*This designation does not entail any recognition of Palestine as a state and is without prejudice to positions on the recognition of Palestine as a state

Organisers and partners


Planets Addiction SAS
  • Judith Aldridge (Senior Lecturer, School of Law, University of Manchester, UK)
  • Alexander Baldacchino (Professor of Medicine, Psychiatry and Addictions, University of St Andrews, UK)
  • Henri Bergeron (Chair in Health Studies, Sciences Po Paris, France)
  • Virginia Berridge (Professor of History and Director, Centre for History in Public Health, London School of Hygiene and Tropical Medicine, UK)
  • Kim Bloomfield (Professor, Center for Alcohol and Drug Research, Aarhus University, Denmark)
  • Henrietta Bowden-Jones (Consultant Psychiatrist. Founder and Director, National Problem Gambling Clinic, UK)
  • Jørgen G. Bramness (Senior researcher, Norwegian National Advisory Unit on Concurrent Substance Abuse and Mental Health Disorders, Norwegian Centre of Dual Diagnosis)
  • Anne Line Bretteville-Jensen (Research Director, Norwegian Institute for Alcohol and Drug Research (SIRUS), Norway)
  • Angelina Brotherhood (Public Health Researcher, Liverpool John Moores University, UK)
  • Rachel Btaiche (Focal Person, National Observatory on Drugs and Drug Addiction, Ministry of Public Health, Lebanon)
  • Gerhard Bühringer (Chair of Addiction Research, Institute for Clinical Psychology and Psychotherapy, Technische Universität Dresden, Germany)
  • Catherine Comiskey (Head of School of Nursing and Midwifery, Trinity College, Ireland)
  • Ornella Corazza (Reader in Substance Addictions and Behaviours, University of Hertfordshire, Hatfield, UK)
  • Paul Dargan (Consultant Physician and Clinical Toxicologist, Guy's and St Thomas' NHS Foundation Trust, and Reader in Toxicology, King’s College London, UK)
  • Marina Davoli (Head, Department of Epidemiology, National Agency for Health Services, Italy)
  • Louisa Degenhardt (Professor, National Drug and Alcohol Research Centre (NDARC), Australia)
  • Zsolt Demetrovics (ELTE Eötvös Loránd University, Budapest, Hungary)
  • Cuneyt Evren (Associate Professor of Psychiatry, Head of Research, Treatment and Training Center for Alcohol and Substance Dependence (AMATEM), Istanbul, Turkey)
  • Fernando Rodríguez de Fonseca (Fundación IMABIS, Hosp. Univ. Carlos Haya de Málaga, Spain)
  • Fabrizio Faggiano (Professor of Public Health at the Department of Translational Medicine of the University of the Piemonte Orientale, Italy)
  • Michael Farrell (Director, National Drug and Alcohol Research Centre (NDARC), University of New South Wales, Australia)
  • Gabriele Fischer (Medical Director of the Addiction Clinic at the Medical University Vienna, Austria)
  • Henk Garretsen (Professor, Director Tranzo, Scientific Centre for Care and Welfare, Tilburg University, The Netherlands)
  • Eilish Gilvarry (President of the Society for the Study of Addiction, Honorary Professor of Addiction Psychiatry, Newcastle University, UK)
  • Manuela Grazina (Professor, Faculty of Medicine; Researcher and Head of Laboratory of Biochemical Genetics, Center for Neuroscience and Cell Biology; University of Coimbra, Portugal)
  • Jason Grebely (Associate Professor, The Kirby Institute, UNSW Sydney, Australia)
  • Antoni Gual (Director of the Addictions Unit, Hospital Clínic Barcelona, Spain)
  • Wayne Hall (Professor, Director and Inaugural Chair, Centre for Youth Substance Abuse Research, The University of Queensland, Australia)
  • Matthew Hickman (School of Social and Community Medicine, University of Bristol, UK)
  • Susana Jiménez-Murcia (Head of Pathological Gambling Unit, Department of Psychiatry, University Hospital of Bellvitge, Barcelona, Spain)
  • Beau Kilmer (Co-director and senior policy researcher, RAND Drug Policy Research Center; Professor, Pardee RAND Graduate School, USA)
  • Dirk Korf (Professor, Bonger Institute of Criminology, University of Amsterdam, The Netherlands)
  • Krzysztof Krajewski (Chair of Criminology, Jagiellonian University, Poland)
  • Ludwig Kraus (Director, IFT Institut für Therapieforschung, Munich, Germany)
  • Håkan Leifman (Director, Swedish Council for Information on Alcohol and Other Drugs (CAN), Sweden)
  • Henrique Lopes (Scientific coordinator of the Public Healthcare Unit of the Portuguese Catholic University / President of the Ibero-latin-american Scientific Society SOCILEJ / President of the Sectorial Commission for Health Quality)
  • Pia Mäkelä (Head of Alcohol and Drugs Unit, National Institute for Health and Welfare, Finland)
  • Meni Malliori (Professor of Psychiatry, Eginition Hospital, National & Kapodistrian University of Athens, Greece)
  • Angela Me (Chief of the Research and and Trend Analysis Branch, United Nations Office on Drugs and Crime)
  • Emília Nunes (Professor, Director of the National Programme for Prevention of Smoking and Tobacco Control, General-Directorate of Health, Portugal)
  • Letizia Paoli (Professor, Leuven Institute of Criminology, University of Leuven, Faculty of Law, Belgium)
  • Amy Porath (Director, Research and Policy, Canadian Centre on Substance Abuse, Canada)
  • Jürgen Rehm (Director, Social and Epidemiological Research (SER) Department, Centre for Addiction and Mental Health, Toronto, Canada)
  • Xavier Majó i Roca (Office of Drug Addiction, Public Health Agency of Catalonia, Spain)
  • Tim Rhodes (Professor of Public Health Sociology, London School of Hygiene and Tropical Medicine (UK)/University of New South Wales (Australia))
  • Zila M. Sanchez (Professor of Epidemiology, Preventive Medicine Department, Universidade Federal de São Paulo, Brazil)
  • Emanuele Scafato (Director of Population’s Health and Health Determinants Unit in the National Centre for Epidemiology, Surveillance and Health Promotion-CNESPS at the Istituto Superiore di Sanità, Italy)
  • Eberhard Schatz (Coordinator CORRELATION network)
  • Janusz Sieroslawski (Institute of Psychiatry and Neurology, Poland)
  • Zili Sloboda (President, Applied Prevention Science, Inc., USA)
  • Rainer Spanagel (Professor of Pharmacology & Toxicology, Head of the Institute of Psychopharmacology, University of Heidelberg, Germany)
  • Kerstin Stenius (Assistant Professor, Centre for Social Research on Alcohol and Drugs, Stockholm University, Sweden; Alcohol and Drugs unit, National Institute for Health and Welfare, Finland; and Nordic Centre for Welfare and Social Issues, Finland)
  • John Strang (Professor, Head of the Addictions Department, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London, UK)
  • Harry Sumnall (Professor, Centre for Public Health, Liverpool John Moores University, UK)
  • Margriet Van Laar (Head of the Department Drug Monitoring, Trimbos Institute, The Netherlands)
  • Julian Vicente (Lead scientist, epidemiology, EMCDDA)
  • Graça Vilar (Director of the Planning and Intervention Department of SICAD, Master in forensic medicine and forensic sciences, Graduate Assistant of Psychiatry Hospital, Portugal)
  • Chris Wilkins (Senior Researcher, Drugs Team Leader, SHORE & Whariki Research Centre, College of Health, Massey University, Auckland, New Zealand)

Co-chairs: Manuel Cardoso (SICAD), Paul Griffiths (EMCDDA)

  • John Marsden (Addiction/SSA)
  • Julia Sinclair (Addiction/SSA)
  • Michal Miovsky (ISAJE)
  • Richard Pates (ISAJE)
  • Ana Sofia Santos (SICAD)
  • Ana Castela Rodrigues (SICAD)
  • Maria Moreira (EMCDDA)
  • Klaudia Palczak (EMCDDA)

Co-chairs: Ana Sofia Santos (SICAD), Maria Moreira (EMCDDA)

  • Ana Castela Rodrigues (SICAD)
  • Sonia Ferreira (SICAD)
  • Filipa Cunha (SICAD)
  • Carla Cachola (SICAD)
  • Elsa Maia (SICAD)
  • Irene Conduto (SICAD)
  • Klaudia Palczak (EMCDDA)
  • Marie-Christine Ashby (EMCDDA)
  • Silke Vitt (EMCDDA)
  • Ângela Antunes (EMCDDA)
  • Renate De Neve (EMCDDA)